Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative depression in osteoarthritis patients undergoing joint arthroplasty
ChiCTR2500106598Phase 4Completed
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) and osteoarthritis (OA) (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Hamilton Depression Rating Scale (HAMD) score. Started Jul 2025; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2500106598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106598.